Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2021 / Article

Research Article | Open Access

Volume 2021 |Article ID 2999296 | https://doi.org/10.1155/2021/2999296

Dandong Fang, Yongbin Wang, Ziyue Zhang, Donghai Yang, Daqian Gu, Bo He, Xiaoqun Zhang, Duofen He, HongYong Wang, Pedro A. Jose, Yu Han, Chunyu Zeng, "Calorie Restriction Protects against Contrast-Induced Nephropathy via SIRT1/GPX4 Activation", Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 2999296, 13 pages, 2021. https://doi.org/10.1155/2021/2999296

Calorie Restriction Protects against Contrast-Induced Nephropathy via SIRT1/GPX4 Activation

Academic Editor: Andrey V. Kozlov
Received03 May 2021
Revised05 Aug 2021
Accepted16 Sep 2021
Published19 Oct 2021


Calorie restriction (CR) extends lifespan and increases resistance to multiple forms of stress, including renal ischemia-reperfusion (I/R) injury. However, whether CR has protective effects on contrast-induced nephropathy (CIN) remains to be determined. In this study, we evaluated the therapeutic effects of CR on CIN and investigated the potential mechanisms. CIN was induced by the intravenous injection of iodinated contrast medium (CM) iopromide (1.8 g/kg) into Sprague Dawley rats with normal food intake or 40% reduced food intake, 4 weeks prior to iopromide administration. We found that CR was protective of CIN, assessed by renal structure and function. CM increased apoptosis, reactive oxygen species (ROS), and inflammation in the renal outer medulla, which were decreased by CR. The silent information regulator 1 (SIRT1) participated in the protective effect of CR on CIN, by upregulating glutathione peroxidase 4 (GPX4), a regulator of ferroptosis, because this protective effect was reversed by EX527, a specific SIRT1 antagonist. Our study showed that CR protected CIN via SIRT1/GPX4 activation. CR may be used to mitigate CIN.

1. Introduction

Contrast-induced nephropathy (CIN) is the abrupt deterioration of renal function resulting from intravenous or intra-arterial administration of iodinated contrast media used in diagnostic coronary angiography or percutaneous coronary intervention [1, 2]. The frequency of CIN ranges from 2% in low-risk patients to 50% in high-risk patients. It is reported to be the third leading cause of hospital-acquired acute renal injury. CIN is associated with increased morbidity, extended length of hospital stays, and increased costs [35]. The precise mechanism underlying CIN is not fully understood. A decrease in renal blood flow, increased reactive oxygen species (ROS) formation, and direct toxic affection renal tubule cells may be involved in the pathogenesis of CIN [6, 7].

There is no specific treatment for established CIN; prevention is the best strategy [8]. Attempts of preventing acute kidney injury with various substances such as N-acetylcysteine, vitamin C, statins, and furosemide have shown variable results. Adequate hydration is considered the basis of all preventive strategies [9]. However, a recent randomized trial found that prophylactic hydration has no benefit in protecting against CIN in patients with preexisting chronic kidney disease; even hydration by itself sometimes leads to complications [10]. There are 6–12 million high-risk patients, including those with preexisting chronic kidney disease, diabetes mellitus, and old age, undergoing procedures with intravascular iodinated contrast administration every year, worldwide [10]. Thus, it is urgent to identify novel preventive measures, especially without side effects; to decrease CIN incidence; and to improve clinical prognosis.

Calorie restriction (CR), via restriction of food intake, is the principal nongenetic or environmental intervention that extends lifespan without significant side effects [11]. Although the mechanisms of CR are complex, the prevention of oxidative stress and maintenance of antioxidant reserves are common features [12, 13]. CR has been proved to affect processes involved in cellular senescence, energy metabolism, stress signaling pathways, and formation of ROS [14]. There is accumulating evidence to indicate that silent information regulator 1 (SIRT1) mediates the effects of CR on metabolic reprogramming at a cellular level [15]. In addition to extending lifespan, CR has also been shown to provide protection against diverse acute tissue injuries, such as myocardial ischemia-reperfusion (I/R) injury [16] and cerebral I/R injury [17]. Mitchell and coworkers showed that a 30% reduction in daily calorie intake over short time periods prevented acute kidney injury in a murine I/R injury model [18]. Similar results have been reported in other models of renal injury [19]. However, whether CR has beneficial effects on CIN remains unclear. The aim of the study was to investigate whether the pretreatment with CR could mitigate CIN in rats and whether the renoprotective effects of CR are mediated by SIRT1 and its downstream pathway.

2. Methods and Materials

2.1. Animals

Adult male Sprague Dawley (SD) rats, weighting  g, were obtained from the Laboratory Animal Center of Daping Hospital. All procedures were performed in accordance with institutional regulations and with the approval of the Experimental Animals Committee of Daping Hospital. The calorie-restricted rats (CR group) were fed 60% of the amount of food consumed by the control group for 4 weeks. Control rats had free access to food and water.

2.2. CIN Model

All the rats were deprived of water 24 h before the induction of CIN or mock CIN. Then, the rats were anesthetized with an intraperitoneal injection of pentobarbital sodium (50 mg/kg) and placed on a heating pad to maintain a constant body temperature of 37°C during the surgery. The left external jugular vein was cannulated with PE-10 tubing. SRT1720 (500 mg/kg), SIRT1 inhibitor EX527 (500 mg/kg), or ferrostatin-1 (Fer-1) (5 mg/kg), dissolved in sterile saline solution, was administrated intravenously, followed by the intravenous injection of contrast medium (CM) (iopromide, 1.8 g/kg). Then, the incisions were sutured, and the rats were allowed to recover for 48 h with free access to food and water. The rats were kept in metabolic cages for 24 h urine collections. The rats were reanesthetized with sodium pentobarbital (50 mg/kg body) at indicated times after CM injection. Then, a laparotomy and nephrectomy were performed. Blood samples obtained from abdominal aorta and the harvested kidneys were stored at −80°C for subsequent analyses.

2.3. Renal Function

The collected blood samples were centrifuged, and the sera were immediately analyzed with commercial kits. The renal function of the rats was assessed by measuring serum creatinine (Cr), blood urea nitrogen (BUN), and creatinine clearance (CCr). Serum samples were analyzed using an automated Beckman Analyzer (Beckman Instruments GmbH, Munich, Germany). Urine creatinine was measured using a Hitachi multianalyzer (Hitachi, 205D; Hitachinaka, Japan). CCr was calculated according to the formula , where is the urinary Cr concentration (μmol/L); is the total urine volume collected for 24 h (mL/min); and is the serum Cr concentration (μmol/L) [20].

2.4. Renal Histopathology

The kidney samples were fixed and then dehydrated in increasing concentrations of ethanol. Subsequently, they were cleared in xylene and embedded in paraffin. The samples were cut into 4 μm thick sections, followed by a staining with haematoxylin and eosin. Morphological damages to the kidney were scored to evaluate the degree of renal damage. These histopathologic damages included tubular epithelial cell swelling and vacuolization, cast formation, and desquamation. Pathological scoring, based on the presence of acute necrosis in proximal tubule cells, was quantified by the calculation of the percent of tubules that displayed cell necrosis, loss of brush border, cast formation, and tubule dilatation. The scale (1-5 points) is as follows: 0, none; 1, 0-10%; 2, 11-25%; 3, 26-45%; 4, 46-75%; and 5, 76-100%, as described previously [21]. At least 7 fields were examined in each slide.

2.5. Apoptosis of CM-Injured Kidney

Apoptotic cell death of kidney was detected using TUNEL assay [22]. In brief, tissue sections, selected from the outer medulla of the kidney, were heated at 65, washed in xylene, and dehydrated through a graded series of ethanol solutions. Next, sections were incubated in 10 μg/mL protease K (Sigma, St Louis, MO) for 30 min at 37 and then with 0.5% Triton X-100 for 10 min. Slides were rinsed twice with PBS and then incubated in 50 μL of TUNEL reaction mixture for 60 min at 37 in a humidified atmosphere in the absence of light. After PBS rinses, the tissue sections and cells were mixed with immunostaining blocking solution for 1 hat room temperature to prevent nonspecific antibody binding. A fluorescein in situ cell death detection kit was used according to the manufacturer’s instructions for TUNEL assay (Roche Applied Science, Mannheim, Germany). Positive cells were counted in ten nonoverlapping fields of the outer medulla in each sample (magnification, ×400). The activity of caspase 3 in the renal outer medulla was measured using a Caspase 3 Colorimetric Assay Kit, following the manufacturer’s protocol (Beyotime, China).

2.6. Measurement of DHE, MDA, SOD, GSH/GSSG, MPO, IL-β, and TNF-α

Oxidative stress of the injured kidney was evaluated by measuring the dihydroethidium (DHE), malondialdehyde (MDA), and superoxide dismutase (SOD) levels and the reduced and oxidized glutathione ratio (GSH/GSSG). The rat kidney tissues were quickly frozen, cut to a thickness of 8 μm at an optimized cutting temperature, and mounted on glass slides [23]. The concentration of DHE in the renal outer medulla was calculated by the fluorescence intensity using ImageJ, according to the manufacturer’s protocol (Beyotime Institute of Biotechnology, China). The renal outer medulla was homogenized in ice-cold sucrose buffer (pH 7.4) for the determination of MDA, SOD, GSH, myeloperoxidase (MPO), IL-1β, and tumor necrosis factor-α (TNF-α) levels. The concentration of MDA in the renal outer medulla was calculated using the thiobarbituric acid method, according to the manufacturer’s protocol (Assay Kit from Nanjing Jiancheng Bioengineering Institute, Nanjing, China). Total SOD activity was evaluated using the nitroblue tetrazolium method according to the manufacturer’s instructions (Beyotime Institute of Biotechnology, China). SOD activity was expressed as units/mg protein. The intracellular levels of GSH were measured using GSH and GSSG Assay Kit (Beyotime Institute of Biotechnology, China). MPO, IL-1β, and TNF-α were used as a marker of inflammatory response, and their levels were determined using ELISA kits (R&D Systems, Minneapolis, MN).

2.7. Western Blot Analysis

Kidney samples (40 mg) were ground and homogenized in ice-cold lysis buffer (20 mmol/L Tris-HCl, pH 7.4; 2 mmol/L EDTA, pH 8.0; 2 mmol/L EGTA; 100 mmol/L NaCl; 10 μg/mL leupeptin; 10 μg/mL aprotinin; 2 mmol/L phenylmethylsulfonyl fluoride; and 1% NP-40). The tissue homogenate was sonicated and kept on ice for one hour. The lysate was centrifuged at for 40 min. The supernatant was collected, and the concentration of the protein was measured by using a protein assay kit (Bio-Rad Laboratories, Hercules, CA) whose standard was bovine serum albumin. The supernatants were boiled in a sample buffer (35 mmol/L Tris-HCl, pH 6.8; 4% SDS; 9.3% dithiothreitol; 0.01% bromophenol blue; and 30% glycerol) for 5 min at 95. The samples were stored at -20 prior to use. Protein samples (50 mg) were separated by SDS-PAGE with 8% polyacrylamide gel and electrotransferred to nitrocellulose membranes. After the nonspecific binding sites were blocked in TBS (Tris-buffered saline) containing 5% nonfat dry milk for 1 hour, the membranes were incubated with primary antibodies with recommended dilution of anti-SIRT1 (Millipore, Bedford, MA; dilution 1 : 500), anti-GPX4 (Proteintech; dilution 1 : 500), anti-total caspase-3, and anti-cleaved caspase-3 (Cell Signaling Technology; dilution 1 : 1000) at 4 overnight. GAPDH (Santa Cruz Biotechnology; dilution 1 : 1000) were used as housekeeping proteins. The membranes were then incubated with the diluted (1: 15000) secondary antibody (Li-Cor Biosciences, Lincoln, NE) at room temperature for 1 hour. Membranes were washed three times with TBST, and the bounds were detected by the Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE). The images were analyzed using the Odyssey Application Software to obtain the integrated intensities (Figure S3 in the Supplementary Material). ImageJ was used to calculate the integrated intensity of the western blots.

2.8. Analysis of Plasma Iodine

Plasma iodine was measured using the Sandell-Kolthoff method [24]. Blood was drawn from the abdominal aorta of rats 15 min after CM injection. The plasma was separated from clotted blood by centrifugation. 0.5 mL perchloric acid and 0.6 mL sodium chlorate solutions were added to 0.1 mL plasma, mixed, and placed in a digestion-controlled heating device at 130for 120 min. Then, the mixture was removed and cooled at 20. 3 mL arsenious acid was added to the just-cooled sample (about 1.2 mL), fully mixed, and allowed to react for 15 min. Add 0.6 mL of ammonium cerium sulfate solution to each tube (about 4.8 mL) in sequence at the same time interval (30 s or 20 s). When the absorbance value of the standard tube 300 μg/L iodine concentration tube reached about 0.10, the absorbance value of each tube was measured. When the iodine concentration in plasma exceeded the measurement threshold, the plasma was diluted accordingly, before the iodine concentration was measured.

2.9. Statistical Analysis

Data are presented as . One-way factorial ANOVA, followed by Dunnett’s post hoc test, was used for multigroup (>2) comparison. was considered significant.

3. Results

3.1. CR Protects Renal Injury in CIN

The rats were studied after 4 weeks of after control diet or CR. The rats after CR ( g) lost about 15 percent of body weight, relative to the control group ( g) (Figure S1(a) in the Supplementary Material). There were no significant differences in plasma cholesterol and glucose levels between two groups (Figures S1(b) and S1(c) in the Supplementary Material). Because the CR mice lost 15% of their body weight and considering the relationship between blood volume and body weight [2528], we measured the plasma iodine concentration 15 min after CM injection. There were no significant differences in plasma iodine concentration between the two groups (Figure S1(d) in the Supplementary Material) (control group,  mg/mL vs. the CR group,  mg/mL). The intravenous injection of CM (iopromide, 1.8 g/kg) caused CIN, proved by the increase in BUN and serum Cr levels and decrease in CCr of the CM group (Figures 1(a)-1(c)). By contrast, in the CR group, relative to the control group, the CM-induced increases in BUN and serum Cr and decrease in CCr were less (Figures 1(a)-1(c)), indicating the protection of CIN by CR.

Consistent with our previous report [29], CIN was characterized by marked proximal tubule dropout, extensive interstitial inflammation, and extensive intratubular cast formation 24 h after CM injection. The main lesion was in the outer medulla. The abovementioned pathological changes were reduced by CR, proved by the reduction in renal pathological scores in HE-stained kidneys (Figure 2(a)).

Apoptosis is one of the major CM-induced cytotoxic effects on the kidney [30]. We found that CM increased apoptosis, determined by TUNEL staining, in the boundary between the cortex and medulla. The TUNEL-positive cells were decreased approximately three times in the CR+CM group, relative to the CM group (Figure 2(b)). Consistent with the decrease in TUNEL-positive cells in the CR+CM group, relative to the CM group, the cleaved caspase 3 protein expression and caspase 3 activity were also elevated in CIN, which were also attenuated by CR pretreatment (Figures 2(c) and 2(d)). Taken together, CR protects from CIN by attenuation of apoptosis.

3.2. The Protective Effect of CR on CIN Is Mediated by SIRT1 Activation

Previous studies indicated the role of SIRT1 in the protection of CR in various diseases, including diabetes [31, 32] and neurodegenerative diseases [33]. Therefore, we wondered whether or not SIRT1 was involved in the protective effect of CR on CIN. Our study showed that SIRT1 expression, determined by immunoblotting, was lower in the CM group, compared with that control group, which was reversed by CR (Figure 3(a)). In the presence of EX527 (500 mg/kg), a specific SIRT1 antagonist, CR-mediated protection on CIN was lost, proved by the higher renal HE scores, serum Cr, and BUN in the CM+EX527+CR than the CM+CR group (Figures 3(b)3(d)). Moreover, the protective effect of CR on CIN was simulated by SRT1720 (500 mg/kg), a SIRT1-specific activator. Pretreatment with the SIRT1 activator SRT1720 mitigated the renal proximal tubule dropout in CIN, detected by renal HE scores, an effect that was blocked by the SIRT1 antagonist EX527 (Figure 4(a)). Moreover, the protective effect of SRT1720 in CIN was also demonstrated by improvement of renal function, shown by the lower serum Cr and BUN levels and higher CCr (Figures 4(b)4(d)); these effects were blocked by the SIRT1 antagonist EX527.

3.3. Role of SIRT1-Mediated Antioxidants, Antiferroptosis, and Anti-Inflammation in the Renal-Protective Effect of CR on CIN

As an antioxidant, SIRT1 plays a protective role in many diseases, via downregulation of ROS formation. Our present study showed that CM increased ROS levels, determined by measurement of DHE, MDA, SOD, and GSH levels [34]. Pretreatment with CR decreased the CM-induced increase in DHE and MDA production (Figures 5(a) and 5(b)) while it increased the CM-induced decrease on SOD and GSH levels in the renal outer medulla (Figures 5(c) and 5(d)). In addition, the protective effect of CR on ROS formation was lost in the presence of the SIRT1 antagonist EX527.

Accumulation of ROS and cell death are reminiscent of ferroptosis [35]. Whereas glutathione peroxidase 4 (GPX4), a regulator of ferroptosis, was decreased after injection of CM, CR alleviated the reduction of GPX4 in CIN that was blocked by EX527 (Figure 5(e)).

Since there is a close relationship between ROS and inflammation, we also checked the inflammation induced by CM by determination of the renal outer medulla MPO, IL-1β, and TNF-α protein levels. Consistent with the ROS levels, CM increased MPO, IL-1β, and TNF-α levels that were decreased by CR. In the presence of EX527, the anti-inflammatory effect of CR in CIN was lost (Figures S2(a)–S2(c) in the Supplementary Material).

3.4. Inhibition of Ferroptosis Prevents Renal Injury in CIN

Many studies have found that ferroptosis plays an important role in kidney diseases [36, 37]. Pretreatment of Fer-1 (5 mg/kg), an inhibitor of ferroptosis, improved renal function in CIN, assessed by HE scores (Figure 6(a)), serum Cr (Figure 6(b)), and BUN (Figure 6(c)). Moreover, we found that Fer-1 could reduce DHE intensity and MDA level (Figures 6(d) and 6(e)) and increase GSH levels (Figure 6(f)) in CIN. Therefore, we confirmed that Fer-1 could reduce the total ROS production in CIN. Therefore, ferroptosis plays an important role in CIN, and inhibition of ferroptosis can inhibit the renal damage caused by CM.

4. Discussion

Although the exact mechanisms that cause CIN are not clear, oxidative stress and inflammation are two major factors that play pivotal roles in the development of CIN. The generation of excessive levels of ROS under hypoxia can directly cause endothelial dysfunction, renal tubular damage, and abnormal tubular transport [38, 39]. Reactive oxygen species imbalance also causes lipid peroxidation that leads to cytotoxic damage [40]. In addition, activation of cytokine-induced inflammatory mediators by reactive free radicals exacerbates the cellular injury [41]. In the present study, increased MDA and decreased SOD and GSH levels were observed in CIN; increased MPO, IL-1β, and TNF-α levels were also found.

CR, a proven powerful strategy to expand lifespan in many animals, was reported to exert protection in chemotherapeutic drug-induced injury [42]. Nutrient signaling activated by CR plays important roles in protection from injury. For example, CR combined with resveratrol, which has antioxidant properties, protects the rat heart from doxorubicin-induced toxicity [43]. CR also enhances cellular adaptation to hypoxia in aged kidneys [44] and ameliorates age-induced structural and functional changes, such as glomerulosclerosis, tubulointerstitial fibrosis, decline in renal blood flow, and loss of several tubular transport functions [45]. CR, a nongenetic and environmental intervention that is free from side effects, may benefit high-risk patients who undergo procedures involving intravascular iodinated contrast administration. In our study, rats with CIN caused by CM and fed a CR diet had a better renal function and structure than the CM group on normal caloric intake, suggesting a protective role of CR in CIN. Indeed, the degree of apoptosis, oxidative stress, and inflammation was attenuated in the CR-treated CM group, relative to the CM group on normal caloric intake, which further confirmed the protective effect of CR in CIN.

Many studies showed that CR is associated with the alterations in energy metabolism. SIRT1, a NAD+-dependent deacetylase, is one of the seven mammalian sirtuins and is known to play an important role in maintaining metabolic homeostasis in many tissues [12, 46]. There are several reports on SIRT1-mediated protection from injury in the brain, kidney and other organs [17, 47, 48]. Relevant to our present study, a previous study elucidated on the ability of SIRT1 activation to protect the renal medulla from oxidative injury in mice [49]. Our present study demonstrated that SIRT1 expression in the renal outer medulla was significantly reduced in CIN. In mice pretreated with CR, renal SIRT1 expression was increased and CIN was attenuated, which showed a protective effect of SIRT1 on CIN in vivo. Furthermore, the protective effect of CR on CIN was mimicked by SRT1720, a SIRT1-specific activator. In the presence of EX527, a specific SIRT1 antagonist, the CR-mediated protection on CIN was lost, confirming that CR-mediated protection from contrast-induced nephropathy occurs via SIRT1 activation.

The term ferroptosis was coined in 2012 [50] to describe the form of cell death induced by the small molecule elastin, which leads to GSH depletion and inactivation of the phospholipid peroxidase GPX4 [51]. Recently, several studies have found that ferroptosis plays a key role in kidney injury [36, 37, 52]. However, the relationship between ferroptosis and CIN is unclear. Our present study demonstrated that renal ferroptosis is an important pathological damage factor in CIN. Moreover, a recent study found that stabilization of the expression of SIRT1 can inhibit ferroptosis-induced cell death [53]. Our current study also found that CR could alleviate the reduction of renal GPX4 after injection of CM, an effect that was blocked by SIRT1 antagonist EX527. In addition, we showed that Fer-1, an inhibitor of ferroptosis, improved the renal function and reduced the oxidative stress in CIN, confirming the involvement of GPX4 in the beneficial effect of CR. However, there are still some questions that need to be answered. For example, how does SIRT1 regulate GPX4 in the kidney? The answer can probably give us a clue to explain the different functions of SIRT1 in different situations.

4.1. Limitation

We realize that the body weight difference between the CR and non-CR group in the calculation of the dosage of CM may influence the results of experiments. Our CR study was performed in SD rats, results of which may be influenced by other rat models, such as the Zucker rat [26], because the obese Zucker rat is much heavier than the control lean Zucker rat. By contrast, in our present study, the control SD rat weights of  g were only 15% higher than CR SD rats with body weights of  g. To determine if the absolute amount of injected CM affected the plasma CM concentration, we measured the plasma iodine concentration by the Sandell-Kolthoff method [24]. We found that there was no significant difference in plasma iodine concentration between the two groups (control group,  mg/mL vs. the CR group,  mg/mL). Moreover, a previous report [54] showed that iodine concentrations, after the unit conversion, from 3.5 to 7.0 g/kg did not affect renal function. To avoid the bias of CM dosage due to the body weight, it is better to ascertain first the plasma CM concentration by measurement of plasma iodine concentration, before doing subsequent experiments.

In conclusion, the present study demonstrated that CR, via SIRT1/GPX4, protects against CIN. CR may be a potential method to prevent CIN.

5. Conclusions

This study revealed a crucial role of CR in extent of CIN in SD rats. We are the first to show that CR can attenuate CIN through its antioxidant and anti-inflammatory effects, via the SIRT1/GPX4 pathway, in renal tissue. SIRT1/GPX4 could be a potential therapeutic target to prevent kidney injury after CM injection in patients.

Data Availability

The research article data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Dandong Fang and Yongbin Wang are co-first authors. Dandong Fang was responsible for data curation, formal analysis, methodology, software, and writing of original draft. Yongbin Wang was responsible for data curation, formal analysis, methodology, and software. Ziyue Zhang was responsible for data curation and formal analysis. Donghai Yang was responsible for the software. Daqian Gu was responsible for the methodology. Bo He was responsible for the supervision and visualization. Xiaoqun Zhang was responsible for the methodology. Duofen He was responsible for the supervision. HongYong Wang was responsible for the investigation and supervision. Yu Han was responsible for the conceptualization, methodology, project administration, writing, review, and editing. Chunyu Zeng was responsible for the conceptualization, funding acquisition, resources, writing, review, and editing.


These studies were supported in part by grants from the National Natural Science Foundation of China (31730043, 31430043), Program of Innovative Research Team by National Natural Science Foundation (81721001), and the National Institutes of Health (7R01DK039308-33, 5P01HL074940-15, and 5R01DK119652-02).

Supplementary Materials

Figure S1: body weight and serum total cholesterol, blood glucose, and plasma iodine levels. (a) Body weights (g) of rats were checked during 4 weeks of CR. Serum samples of rats were collected to measure the levels of serum total cholesterol (b) and blood glucose (c) after 4 weeks of CR. (d) Plasma iodine (mg/mL) concentrations of the control, non-CR group, and CR group were measured 15 minutes after injection of CM. The values are presented as (, vs. control). Figure S2: role of SIRT1 in the anti-inflammatory effects of CR in CIN. SD rats were pretreated with CR for 4 weeks. CIN was induced by intravenous injection of the CM iopromide (1.8 g/kg). The SIRT1 inhibitor EX527 (500 m/kg) was injected intravenously before establishment of CIN. The kidney samples were collected 24 h after CM injection. MPO activity (a) and IL-1β (b) and TNF-α (c) levels in the renal outer medulla were measured to determine the inflammatory response ( vs. control). The values are presented as (, vs. control, # vs. CM alone, & vs. CM+CR). Figure S3: original western blot images. (a) and (b): refer to Figure 2(c). (c) and (d): refer to Figure 3(a). (e) and (f): refer to Figure 5(e). (Supplementary Materials)


  1. J. Golshahi, H. Nasri, and M. Gharipour, “Contrast-induced nephropathy; a literature review,” J Nephropathol title, vol. 3, no. 2, pp. 51–56, 2014. View at: Google Scholar
  2. O. Rewa and S. M. Bagshaw, “Acute kidney injury--epidemiology, outcomes and economics,” Nature Reviews Nephrology, vol. 10, no. 4, pp. 193–207, 2014. View at: Publisher Site | Google Scholar
  3. S. W. Murphy, B. J. Barrett, and P. S. Parfrey, “Contrast nephropathy,” Journal of the American Society of Nephrology, vol. 11, no. 1, pp. 177–182, 2000. View at: Publisher Site | Google Scholar
  4. M. Maeder, M. Klein, T. Fehr, and H. Rickli, “Contrast nephropathy: review focusing on prevention,” Journal of the American College of Cardiology, vol. 44, no. 9, pp. 1763–1771, 2004. View at: Publisher Site | Google Scholar
  5. Z. S. Rancic, “Commentary on 'contrast induced nephropathy and long-term renal decline after percutaneous transluminal angioplasty for symptomatic peripheral arterial disease',” European Journal of Vascular and Endovascular Surgery, vol. 51, no. 3, p. 394, 2016. View at: Publisher Site | Google Scholar
  6. M. Tepel, P. Aspelin, and N. Lameire, “Contrast-induced nephropathy: a clinical and evidence-based approach,” Circulation title, vol. 113, no. 14, pp. 1799–1806, 2006. View at: Publisher Site | Google Scholar
  7. R. Morcos, M. Kucharik, P. Bansal et al., “Contrast-induced acute kidney injury: review and practical update,” Clinical Medicine Insights: Cardiology, vol. 13, article 117954681987868, 2019. View at: Publisher Site | Google Scholar
  8. C. Mamoulakis, K. Tsarouhas, I. Fragkiadoulaki et al., “Contrast-induced nephropathy: basic concepts, pathophysiological implications and prevention strategies,” Pharmacology & Therapeutics, vol. 180, pp. 99–112, 2017. View at: Publisher Site | Google Scholar
  9. D. Markota, I. Markota, B. Starčević, M. Tomić, Z. Prskalo, and I. Brizić, “Prevention of contrast-induced nephropathy with Na/K citrate,” European Heart Journal, vol. 34, no. 30, pp. 2362–2367, 2013. View at: Publisher Site | Google Scholar
  10. E. C. Nijssen, R. J. Rennenberg, P. J. Nelemans et al., “Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non- inferiority trial,” The Lancet, vol. 389, no. 10076, pp. 1312–1322, 2017. View at: Publisher Site | Google Scholar
  11. S. J. Mitchell, J. Madrigal-Matute, M. Scheibye-Knudsen et al., “Effects of sex, strain, and energy intake on hallmarks of aging in mice,” Cell Metabolism, vol. 23, no. 6, pp. 1093–1112, 2016. View at: Publisher Site | Google Scholar
  12. J. A. Baur, Z. Ungvari, R. K. Minor, D. G. Le Couteur, and R. de Cabo, “Are sirtuins viable targets for improving healthspan and lifespan?” Nature Reviews Drug Discovery, vol. 11, no. 6, pp. 443–461, 2012. View at: Publisher Site | Google Scholar
  13. L. M. Redman, S. R. Smith, J. H. Burton, C. K. Martin, D. Il'yasova, and E. Ravussin, “Metabolic slowing and reduced oxidative damage with sustained caloric restriction support the rate of living and oxidative damage theories of aging,” Cell Metabolism, vol. 27, no. 4, pp. 805–815.e4, 2018. View at: Publisher Site | Google Scholar
  14. D. Il'yasova, L. Fontana, M. Bhapkar et al., “Effects of 2 years of caloric restriction on oxidative status assessed by urinary F2-isoprostanes: the CALERIE 2 randomized clinical trial,” Aging Cell, vol. 17, no. 2, p. e12719, 2018. View at: Publisher Site | Google Scholar
  15. S. R. Spindler, “Caloric restriction: from soup to nuts,” Ageing Research Reviews, vol. 9, no. 3, pp. 324–353, 2010. View at: Publisher Site | Google Scholar
  16. S. Rohrbach, M. Aslam, B. Niemann, and R. Schulz, “Impact of caloric restriction on myocardial ischaemia/reperfusion injury and new therapeutic options to mimic its effects,” British Journal of Pharmacology, vol. 171, no. 12, pp. 2964–2992, 2014. View at: Publisher Site | Google Scholar
  17. M. Ran, Z. Li, L. Yang, L. Tong, L. Zhang, and H. Dong, “Calorie restriction attenuates cerebral ischemic injury via increasing SIRT1 synthesis in the rat,” Brain Research, vol. 1610, pp. 61–68, 2015. View at: Publisher Site | Google Scholar
  18. L. T. Robertson, J. H. Treviño-Villarreal, P. Mejia et al., “Protein and calorie restriction contribute additively to protection from renal ischemia reperfusion injury partly via leptin reduction in male mice,” The Journal of Nutrition, vol. 145, no. 8, pp. 1717–1727, 2015. View at: Publisher Site | Google Scholar
  19. M. Calvo-Rubio, M. I. Burón, G. López-Lluch et al., “Dietary fat composition influences glomerular and proximal convoluted tubule cell structure and autophagic processes in kidneys from calorie-restricted mice,” Aging Cell, vol. 15, no. 3, pp. 477–487, 2016. View at: Publisher Site | Google Scholar
  20. A. Kodama, H. Watanabe, R. Tanaka et al., “A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy,” Kidney International, vol. 83, no. 3, pp. 446–454, 2013. View at: Publisher Site | Google Scholar
  21. V. Y. Melnikov, S. Faubel, B. Siegmund, M. S. Lucia, D. Ljubanovic, and C. L. Edelstein, “Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice,” Journal of Clinical Investigation, vol. 110, no. 8, pp. 1083–1091, 2002. View at: Publisher Site | Google Scholar
  22. E. E. Llopart, R. E. Cian, M. M. E. López-Oliva, Á. Zuleta, A. Weisstaub, and S. R. Drago, “Colonic and systemic effects of extruded whole-grain sorghum consumption in growing Wistar rats,” British Journal of Nutrition, vol. 118, no. 8, pp. 589–597, 2017. View at: Publisher Site | Google Scholar
  23. R. Li, X. Meng, Y. Zhang et al., “Testosterone improves erectile function through inhibition of reactive oxygen species generation in castrated rats,” PeerJ, vol. 4, p. e2000, 2016. View at: Publisher Site | Google Scholar
  24. C. P. Shelor and P. K. Dasgupta, “Review of analytical methods for the quantification of iodine in complex matrices,” Analytica Chimica Acta, vol. 702, no. 1, pp. 16–36, 2011. View at: Publisher Site | Google Scholar
  25. M. Subramanian, V. Kurawattimath, K. Pocha et al., “Role of hepatic blood flow and metabolism in the pharmacokinetics of ten drugs in lean, aged and obese rats,” Xenobiotica, vol. 44, no. 12, pp. 1108–1116, 2014. View at: Publisher Site | Google Scholar
  26. A. M. Schreihofer, C. D. Hair, and D. W. Stepp, “Reduced plasma volume and mesenteric vascular reactivity in obese Zucker rats,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 288, no. 1, pp. R253–R261, 2005. View at: Publisher Site | Google Scholar
  27. H. B. Lee and M. D. Blaufox, “Blood volume in the rat,” J Nucl Med title, vol. 26, no. 1, pp. 72–76, 1985. View at: Google Scholar
  28. P. B. Dean, L. Kivisaari, and M. Kormano, “Does dilution of contrast media affect contrast enhancement? An experimental study in rats,” Investigative Radiology, vol. 23, Supplement 1, pp. S118–S121, 1988. View at: Publisher Site | Google Scholar
  29. Z. Gao, Y. Han, Y. Hu et al., “Targeting HO-1 by epigallocatechin-3-gallate reduces contrast-induced renal injury via anti-oxidative stress and anti-inflammation pathways,” PLoS One, vol. 11, no. 2, 2016. View at: Publisher Site | Google Scholar
  30. G. Romano, C. Briguori, C. Quintavalle et al., “Contrast agents and renal cell apoptosis,” European Heart Journal, vol. 29, no. 20, pp. 2569–2576, 2008. View at: Publisher Site | Google Scholar
  31. X. Lang, N. Zhao, Q. He et al., “Treadmill exercise mitigates neuroinflammation and increases BDNF via activation of SIRT1 signaling in a mouse model of T2DM,” Brain Research Bulletin, vol. 165, pp. 30–39, 2020. View at: Publisher Site | Google Scholar
  32. M. Kitada, A. Takeda, T. Nagai, H. Ito, K. Kanasaki, and D. Koya, “Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes,” Experimental Diabetes Research, vol. 2011, Article ID 908185, 11 pages, 2011. View at: Publisher Site | Google Scholar
  33. J. Graff, M. Kahn, A. Samiei et al., “A dietary regimen of caloric restriction or pharmacological activation of sirt1 to delay the onset of neurodegeneration,” Journal of Neuroscience, vol. 33, no. 21, pp. 8951–8960, 2013. View at: Publisher Site | Google Scholar
  34. D. Gu, Y. Shi, Z. Gong et al., “Adiporon, an adiponectin receptor agonist, protects contrast-induced nephropathy by suppressing oxidative stress and inflammation via activation of the AMPK pathway,” Clinical and Experimental Nephrology, vol. 24, no. 11, pp. 989–998, 2020. View at: Publisher Site | Google Scholar
  35. B. R. Stockwell, J. P. F. Angeli, H. Bayir et al., “Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease,” Cell, vol. 171, no. 2, pp. 273–285, 2017. View at: Publisher Site | Google Scholar
  36. A. Belavgeni, C. Meyer, J. Stumpf, C. Hugo, and A. Linkermann, “Ferroptosis and necroptosis in the kidney,” Cell Chemical Biology, vol. 27, no. 4, pp. 448–462, 2020. View at: Publisher Site | Google Scholar
  37. D. Martin-Sanchez, O. Ruiz-Andres, J. Poveda et al., “Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid-induced AKI,” Journal of the American Society of Nephrology, vol. 28, no. 1, pp. 218–229, 2017. View at: Publisher Site | Google Scholar
  38. Z. Z. Liu, V. U. Viegas, A. Perlewitz et al., “Iodinated contrast media differentially affect afferent and efferent arteriolar tone and reactivity in mice: a possible explanation for reduced glomerular filtration rate,” Radiology, vol. 265, no. 3, pp. 762–771, 2012. View at: Publisher Site | Google Scholar
  39. P. B. Persson and M. Tepel, “Contrast medium-induced nephropathy: the pathophysiology,” Kidney International, vol. 69, pp. S8–S10, 2006. View at: Publisher Site | Google Scholar
  40. A. Caiazza, L. Russo, M. Sabbatini, and D. Russo, “Hemodynamic and tubular changes induced by contrast media,” BioMed Research International, vol. 2014, Article ID 578974, 7 pages, 2014. View at: Publisher Site | Google Scholar
  41. C. Quintavalle, M. Brenca, F. De Micco et al., “_In vivo_ and _in vitro_ assessment of pathways involved in contrast media- induced renal cells apoptosis,” Cell Death & Disease, vol. 2, no. 5, p. e155, 2011. View at: Publisher Site | Google Scholar
  42. U. M. Apte, “Upregulated promitogenic signaling via cytokines and growth factors: potential mechanism of robust liver tissue repair in calorie-restricted rats upon toxic challenge,” Toxicological Sciences, vol. 69, no. 2, pp. 448–459, 2002. View at: Publisher Site | Google Scholar
  43. D. Dutta, J. Xu, M. L. Dirain, and C. Leeuwenburgh, “Calorie restriction combined with resveratrol induces autophagy and protects 26-month-old rat hearts from doxorubicin-induced toxicity,” Free Radical Biology and Medicine, vol. 74, pp. 252–262, 2014. View at: Publisher Site | Google Scholar
  44. S. Kume, T. Uzu, K. Horiike et al., “Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney,” Journal of Clinical Investigation, vol. 120, no. 4, pp. 1043–1055, 2010. View at: Publisher Site | Google Scholar
  45. K. M. Kim, K. W. Chung, H. O. Jeong et al., “MMP2-A2M interaction increases ECM accumulation in aged rat kidney and its modulation by calorie restriction,” Oncotarget, vol. 9, no. 5, pp. 5588–5599, 2018. View at: Publisher Site | Google Scholar
  46. P. Oberdoerffer, S. Michan, M. McVay et al., “SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging,” Cell, vol. 135, no. 5, pp. 907–918, 2008. View at: Publisher Site | Google Scholar
  47. X.-L. Zhou, J.-J. Xu, Y.-H. Ni et al., “SIRT1 activator (SRT1720) improves the follicle reserve and prolongs the ovarian lifespan of diet-induced obesity in female mice via activating SIRT1 and suppressing mTOR signaling,” Journal of Ovarian Research, vol. 7, no. 1, 2014. View at: Publisher Site | Google Scholar
  48. Q. Hong, L. Zhang, B. Das et al., “Increased podocyte sirtuin-1 function attenuates diabetic kidney injury,” Kidney International, vol. 93, no. 6, pp. 1330–1343, 2018. View at: Publisher Site | Google Scholar
  49. W.-F. Li, K. Yang, P. Zhu et al., “Genistein ameliorates ischemia/reperfusion-induced renal injury in a SIRT1-dependent manner,” Nutrients, vol. 9, no. 4, p. 403, 2017. View at: Publisher Site | Google Scholar
  50. S. J. Dixon, K. M. Lemberg, M. R. Lamprecht et al., “Ferroptosis: an iron-dependent form of nonapoptotic cell death,” Cell, vol. 149, no. 5, pp. 1060–1072, 2012. View at: Publisher Site | Google Scholar
  51. W. S. Yang, R. SriRamaratnam, M. E. Welsch et al., “Regulation of ferroptotic cancer cell death by gpx4,” Cell, vol. 156, no. 1-2, pp. 317–331, 2014. View at: Publisher Site | Google Scholar
  52. F. Deng, I. Sharma, Y. Dai, M. Yang, and Y. S. Kanwar, “Myo-inositol oxygenase expression profile modulates pathogenic ferroptosis in the renal proximal tubule,” Journal of Clinical Investigation, vol. 129, no. 11, pp. 5033–5049, 2019. View at: Publisher Site | Google Scholar
  53. S. Ma, L. Sun, W. Wu, J. Wu, Z. Sun, and J. Ren, “USP22 protects against myocardial ischemia-reperfusion injury via the SIRT1-p53/SLC7A11-dependent inhibition of ferroptosis-induced cardiomyocyte death,” Frontiers in Physiology, vol. 11, 2020. View at: Publisher Site | Google Scholar
  54. W. Cheng, F. Zhao, C.-Y. Tang, X.-W. Li, M. Luo, and S.-B. Duan, “Comparison of iohexol and iodixanol induced nephrotoxicity, mitochondrial damage and mitophagy in a new contrast-induced acute kidney injury rat model,” Archives of Toxicology, vol. 92, no. 7, pp. 2245–2257, 2018. View at: Publisher Site | Google Scholar

Copyright © 2021 Dandong Fang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.